AbbVie Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $4.23B | $4.28B | $4.86B | $11.84B | $11.54B | $4.62B | $7.88B | $5.69B |
| Depreciation & Amortization | — | — | — | — | — | — | — | — |
| Depreciation | $762.0M | $764.0M | $752.0M | $778.0M | $803.0M | $666.0M | $464.0M | $471.0M |
| Amortization | $7.38B | $7.62B | $7.95B | $7.69B | $7.72B | $5.81B | $1.55B | $1.29B |
| Stock-Based Compensation | $955.0M | $911.0M | $747.0M | $671.0M | $692.0M | $753.0M | $430.0M | $421.0M |
| Net Cash from Operating Activities | $19.03B | $18.81B | $22.84B | $24.94B | $22.78B | $17.59B | $13.32B | $13.43B |
| Investing Activities | ||||||||
| Capital Expenditures | $1.21B | $974.0M | $777.0M | $695.0M | $787.0M | $798.0M | $552.0M | $638.0M |
| Business Acquisitions | $204.0M | $17.49B | $0 | $255.0M | $525.0M | $38.26B | $0 | $0 |
| Net Cash from Investing Activities | $-6.64B | $-20.82B | $-2.01B | $-623.0M | $-2.34B | $-37.56B | $596.0M | $-1.01B |
| Financing Activities | ||||||||
| Dividends Paid | $11.66B | $11.03B | $10.54B | $10.04B | $9.26B | $7.72B | $6.37B | $5.58B |
| Stock Repurchases | $980.0M | $1.71B | $1.97B | $1.49B | $934.0M | $978.0M | $629.0M | $12.01B |
| Net Cash from Financing Activities | $-12.72B | $-5.21B | $-17.22B | $-24.80B | $-19.04B | $-11.50B | $18.71B | $-14.40B |
| Net Change in Cash | $-295.0M | $-7.29B | $3.61B | $-545.0M | $1.30B | $-31.48B | $32.64B | $-2.01B |
| Free Cash Flow | $17.82B | $17.83B | $22.06B | $24.25B | $21.99B | $16.79B | $12.77B | $12.79B |